1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Brother Enterprises Holding Co., Ltd. Class A

Brother Enterprises Holding Co., Ltd. Class A

SSZSE:002562
4.46
CNY
+0.05
(+1.13%)
0.12EPS
36.11P/E
4.97BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.2
1.19
1.31
1.27
1.82
1.95
1.43
2.05
2.89
3.24
2.73
3.37
3.42
3.42
Basic EPS, GAAP
0.03
0.06
0.12
0.2
0.47
0.03
0.05
0.03
0.03
0.29
-0.17
0.04
0.09
0.12
Free Cash Flow per Basic Share
0.01
- -
0.01
-0.21
-0.23
-0.3
-0.74
-0.36
-0.19
-0.01
-0.35
-0.1
-0.06
- -
Dividend per Share
0.02
0.01
0.04
- -
0.06
0.15
0.11
0.04
0.03
0.04
0.18
0.05
0.05
0.14
Book Value per Share
1.15
1.21
1.93
2.04
2.64
2.57
2.57
3.19
2.82
3.17
2.87
2.91
3.23
3.19
Tangible Book Value per Share
1.11
1.16
1.83
1.94
2.5
2.44
2.44
3.01
2.65
3.01
2.72
2.77
3.1
3.07
Basic Weighted Avg Shares
655
674
693
838
858
727
877
934
944
1,054
1,032
1,020
1,057
1,123
Sales/Revenue/Turnover
784
801
905
1,063
1,565
1,415
1,258
1,919
2,733
3,411
2,821
3,441
3,612
3,840
Operating Margin (%)
4.48
6.55
12.81
19.46
31.67
4.68
4.75
8.18
1.82
13.84
-1.76
4.11
6.47
7.57
Depreciation Expense
38
54
59
60
113
146
164
248
291
312
325
353
380
- -
Net Income, GAAP
18
40
82
168
403
22
44
28
28
306
-175
41
95
135
Effective Tax Rate (%)
14.74
15.47
10.03
16.78
14.69
66.47
7.62
31.96
- -
18.73
- -
20.49
15.8
12.56
Profit Margin (%)
2.35
5
9.08
15.77
25.76
1.54
3.48
1.46
1.04
8.96
-6.22
1.19
2.63
3.52
Working Capital
296
312
1,051
558
1,319
667
440
556
470
376
-886
-652
334
391
LT Debt
- -
- -
- -
1
528
505
763
841
883
528
144
317
629
681
Total Equity
800
839
1,705
1,764
2,286
2,259
2,317
3,027
2,995
3,373
3,054
3,100
3,688
3,647
Return on Invested Capital (%)
0.73
3.71
7.13
11.24
17.39
0.83
1.47
0.82
- -
6.89
- -
0.89
2
2.73
Return on Capital (%)
4.36
4.82
4.78
8.25
17.49
1.14
2.35
1.56
- -
7.58
- -
1.81
2.79
3.42
Return on Common Equity (%)
2.37
4.97
6.59
9.76
19.91
0.96
1.92
1.05
0.94
9.6
-5.46
1.33
2.8
4

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
964
913
890
LT Borrowings
620
680
673
LT Finance Leases
8
8
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,143
1,143
1,143
Market Capitalization
7,383
6,960
4,971

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,123
2,148
2,133
Cash, Cash Equivalents & STI
522
522
550
Accounts Receivable, Net
467
567
528
Inventories
987
910
937
Total Current Liabilities
1,789
1,718
1,742
Payables & Accruals
- -
- -
- -
ST Debt
964
913
890
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.76%
4.52%
18.98%
Free Cash Flow
-231.53%
414.25%
-34.49%
Net Income, GAAP
104.64%
166.37%
133.02%
Sales/Revenue/Turnover
17.34%
15.38%
4.95%
Total Cash Common Dividend
2,948.31%
59.9%
-7.43%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
931
849
842
3,441
2025
919
892
- -
886
3,612
2026
987
1,074
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
0.04
0.02
0.01
0.04
2025
0.02
0.04
- -
-0.01
0.09
2026
0.03
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.05
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.11
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jianping Li
Full Time Employees
2,914
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No.1 Xuelin Street Haining ZH China 314400
IPO Date
Mar 1, 2011
Website
brother.com.cn
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Brother Enterprises Holding Co., Ltd. (002562.SZ) engages primarily in the research, development, manufacture, and sale of nutritional feed additives and premixes for the animal nutrition industry. The company offers a comprehensive portfolio of products including vitamins such as vitamin A, vitamin D3, vitamin E, vitamin C, and biotin; carotenoids like beta-carotene and canthaxanthin; and premixes tailored for livestock, poultry, aquatic animals, and pets; as well as services in customized formulation and technical support for feed production. It operates through segments encompassing vitamin production, premix blending, and chemical synthesis, serving major customers in animal husbandry, aquaculture, and pet food sectors across China and select international markets including Southeast Asia and Europe. Founded in 1998 and headquartered in Ningbo, Zhejiang Province, China, the company maintains production facilities in multiple provinces and subsidiaries focused on R&D and global distribution. In recent developments, Brother Enterprises has expanded its production capacity through strategic investments in new vitamin synthesis lines and formed alliances with international partners for sustainable sourcing of raw materials; additionally, it launched enhanced premix solutions for antibiotic-free animal feed in 2024 amid China's regulatory shifts toward greener agriculture, while pursuing acquisitions in the functional feed additives space to bolster its market position.